Business Description
Inoviq Ltd
ISIN : AU0000196149
Total Employee Number:
5Description
Inoviq Ltd is engaged in developing and commercializing a portfolio of diagnostic and exosome-based products to improve the diagnosis and treatment of cancer and other diseases. The company has commercialized the hTERT test used as an adjunct to urine cytology testing for bladder cancer and the EXO-NET pan-exosome capture tool for research purposes. Its cancer diagnostic pipeline includes blood tests in development for earlier detection and monitoring of ovarian, breast, prostate, and other cancers. The Group operates predominantly in one business segment, the research and development of cancer diagnostics, and two geographical segments, Victoria, Australia, and the United States of America, with the majority of revenue coming from Australia.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 50.92 | |||||
Equity-to-Asset | 0.91 | |||||
Debt-to-Equity | 0.01 | |||||
Debt-to-EBITDA | -0.03 | |||||
Piotroski F-Score | 2/9 | |||||
Altman Z-Score | 4.66 | |||||
Beneish M-Score | -3.23 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 18.6 | |||||
3-Year EBITDA Growth Rate | 5.5 | |||||
3-Year EPS without NRI Growth Rate | 5.7 | |||||
3-Year FCF Growth Rate | 15.4 | |||||
3-Year Book Growth Rate | -21.2 |
Momentum Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 29.2 | |||||
9-Day RSI | 31.66 | |||||
14-Day RSI | 35.11 | |||||
3-1 Month Momentum % | 23.53 | |||||
6-1 Month Momentum % | 13.51 | |||||
12-1 Month Momentum % | 13.51 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 7.56 | |||||
Quick Ratio | 7.54 | |||||
Cash Ratio | 6.78 | |||||
Days Inventory | 114.69 | |||||
Days Sales Outstanding | 547.5 | |||||
Days Payable | 2946.93 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -6.7 | |||||
Shareholder Yield % | -32.48 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 78.6 | |||||
Operating Margin % | -1578.6 | |||||
Net Margin % | -1269.65 | |||||
EBITDA Margin % | -1578.6 | |||||
FCF Margin % | -891.75 | |||||
OCF Margin % | -876.32 | |||||
ROE % | -37.13 | |||||
ROA % | -33.84 | |||||
ROIC % | -86 | |||||
3-Year ROIIC % | 12.44 | |||||
ROC (Joel Greenblatt) % | -875.01 | |||||
ROCE % | -45.73 |
GF Value Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 40 | |||||
PB Ratio | 1.27 | |||||
Price-to-Tangible-Book | 2 | |||||
EV-to-EBIT | -1.62 | |||||
EV-to-EBITDA | -1.62 | |||||
EV-to-Revenue | 25.66 | |||||
EV-to-FCF | -3.15 | |||||
Price-to-GF-Value | 0.39 | |||||
| Price-to-Net-Current-Asset-Value | 2.22 | |||||
| Price-to-Net-Cash | 2.5 | |||||
Earnings Yield (Greenblatt) % | -61.59 | |||||
FCF Yield % | -18.05 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Inoviq Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil A$) | 0.57 | ||
| EPS (TTM) (A$) | -0.061 | ||
| Beta | 0.9064 | ||
| 3-Year Sharpe Ratio | -0.1 | ||
| 3-Year Sortino Ratio | -0.19 | ||
| Volatility % | 71.81 | ||
| 14-Day RSI | 35.11 | ||
| 14-Day ATR (A$) | 0.03334 | ||
| 20-Day SMA (A$) | 0.302625 | ||
| 12-1 Month Momentum % | 13.51 | ||
| 52-Week Range (A$) | 0.19 - 0.565 | ||
| Shares Outstanding (Mil) | 140.78 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Inoviq Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Inoviq Ltd Stock Events
| Event | Date | Price (A$) | ||
|---|---|---|---|---|
| 0.033333:1 Stock Split | 2020-12-01 | 0.66 (-4.35%) | ||
| 0.1:1 Stock Split | 2008-09-11 | 4.61 (-4.76%) | ||
| 1.11111:1 Stock Split | 1994-02-08 | 107.99 (+0.00%) | ||
| 1.14286:1 Stock Split | 1991-12-16 | 22.05 (+0.00%) | ||
| 0.1:1 Stock Split | 1990-06-22 | 15.75 (+0.00%) | ||
| 0.933358:1 Stock Split | 1988-05-23 | 421.83 (+0.00%) |
Show
Entries
Inoviq Ltd Frequently Asked Questions
What is Inoviq Ltd(ASX:IIQ)'s stock price today?
The current price of ASX:IIQ is A$0.20. The 52 week high of ASX:IIQ is A$0.56 and 52 week low is A$0.19.
When is next earnings date of Inoviq Ltd(ASX:IIQ)?
The next earnings date of Inoviq Ltd(ASX:IIQ) is .
Does Inoviq Ltd(ASX:IIQ) pay dividends? If so, how much?
Inoviq Ltd(ASX:IIQ) does not pay dividend.
Articles on Inoviq Ltd
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers